PATENT CLAIM ANALYSIS

Application Number: 16227940
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["544", "360000"]

Abstract:
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Claim (Index 29):
The method of  claim 28  wherein the autoimmune inflammatory disease comprises inflammatory bowel disease.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 98.0
- Lexical Diversity: 1.25
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15374556', '15795906', '16007151', '14662506', '13100795']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8554606703673908
- 35 USC 102 Novelty (BERT): 0.5668803021962607
- Combined Prediction Score: 0.8266026335502779
- Mean Citation Score: 568.43998
- Max Citation Score: 638.2203
- Similarity Product: 335.75578018748763

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test